

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO.	SERIAL NO.
		1908-006-27	10/009,344
		APPLICANT	
		WAINER, Irving, et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE	GROUP ART UNIT
		08 APRIL 2002	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
BB	AA	4,837,306	06-06-89	LING, et al.			
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AF				
	AG				
	AH				
	AI				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

BB	AJ	Wallsten, et al., "Entrapment of lipid vesicles and membrane protein-lipid vesicles in gel bead pores", Biochim. Biophys. Acta, 982:47-52 (1989).
BB	AK	Yang, et al., "Steric Immobilization of Liposomes in Chromatographic Gel Beads and Incorporation of Integral Membrane Proteins into Their Lipid Bilayers", Anal. Biochem., 218:210-221 (1994).
BB	AL	Zhang, et al., "Development of an Immobilized P-glycoprotein Stationary Phase for on-line Liquid Chromatographic Determination of Binding Affinities", Journal of Chromatography. B, Biomedical Sciences and Applications, 739(1):33-37 (2000).
BB	AM	Gianni, et al., "Human Pharmacokinetic Characterization and In-vitro Study of the Interaction Between Doxorubicin and Paclitaxel in Patient with Breast Cancer", Journal of Clinical Oncology, 15(5):1906-1915 (1997).
BB	AN	Sparreboom, et al., "Clinical Pharmacokinetics of Doxorubicin in Combination with GF 120918, a Potent Inhibitor of MDRI-P-glycoprotein", Anti-Cancer Drugs, 10(8):719-728 (1999).
BB	AO	Kubota, et al., "Pirarubicin might partly circumvent the P-glycoprotein-mediated Drug Resistance of Human Breast Cancer Tissues", Anticancer Research, 18(2A):967-972 (1998).
	AR	

EXAMINER

Ailene R. Babu

DATE CONSIDERED

4/18/05

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.